AzTrials
AzTrials

Acute Otitis MediaPARENT-EARNCT07640568

Parent-led Assessment and Recognition of AOM Using Digital Ear Imaging

A study testing Assigning of a digital otoscope to the families in the intervention group in people with Acute Otitis Media and Otitis Media, run by Turku University Hospital at 2 sites in Finland.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Acute otitis media (AOM) is the most common bacterial infection in young children and a major contributor to healthcare utilization and costs. Diagnosis relies on otoscopy and identification of tympanic membrane (TM) bulging, yet physician-performed otoscopy has variable diagnostic accuracy and depends heavily on… Read more about this study

Who is it for?
Ages 12 to 47 monthsHealthy volunteers can take part
Conditions the study is for
Acute Otitis Media, Otitis Media
What is being tested?
Assigning of a digital otoscope to the families in the intervention group
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
2 sitesFinland
Study dates
1 Sep 2026to 31 Aug 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 to 47 months
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • At least one episode of AOM within the last 12 months
  • Family speaks fluent Finnish

Who cannot join

  • Tympanostomy tubes or perforation of the TM, or scheduled for upcoming tympanostomy
  • Middle ear fluid at the time of recruitment
  • Previously diagnosed hearing loss
  • Immunosuppressive disorder or medication, excluding inhaled corticosteroids
  • Anatomic defect or anomaly affecting the susceptibility to AOM
  • Previous otoscopy experience of the participating parent

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Simo Nuuttila, MD contact

+358503314426

simo.c.nuuttila@utu.fi

Paula A Tähtinen, MD, PhD contact

+35823130000

paula.tahtinen@utu.fi

Finland2 sites, 2 recruiting
  • Turku University Hospital

    Turku, Southwest Finland, 20521

    Paula A Tähtinen, MD, PhD, +35823130000, paula.tahtinen@utu.fi

    Lotta E Ivaska, MD, PhD, +35823130000, lesaar@utu.fi

    Not yet recruiting
  • Vaasa Central Hospital

    Vaasa, Pohjanmaa, 65130

    Simo Nuuttila, MD, +358503314426, simo.c.nuuttila@utu.fi

    Lisa Kulppi, MD, +35862181111, lisa.kulppi@ovph.fi

    Recruiting

Other trials in Finland

About this study

Acute otitis media (AOM) is the most common bacterial infection in young children and a major contributor to healthcare utilization and costs. Diagnosis relies on otoscopy and identification of tympanic membrane (TM) bulging, yet physician-performed otoscopy has variable diagnostic accuracy and depends heavily on clinical expertise.

Digital otoscopy combined with artificial intelligence (AI)-based image analysis has demonstrated high diagnostic accuracy in previous studies. In a recent study by our group, digital otoscopy with an automated neural network classifier reliably ruled out otitis media in children.

Read more

The PARENT-EAR randomized controlled pilot trial aims to evaluate whether parent-performed digital otoscopy at home, combined with retrospective AI analysis of captured TM images, can reduce physician visits due to suspicion of AOM. The study also assesses feasibility, diagnostic accuracy of parents after training, and potential effects on antibiotic use and healthcare utilization.

Methods and outcomes The PARENT-EAR trial is a randomized controlled pilot trial conducted at Vaasa Central Hospital and Turku University Hospital. Recruitment will occur between September and December 2026 (extended if necessary), with follow-up ending May 31, 2027 (5-9 months per participant).

Children aged 12 to 47 months with at least one AOM episode in the past 12 months will be randomized 1:1 using permuted block randomization. Exclusion criteria include tympanostomy tubes, tympanic membrane perforation, middle ear effusion at recruitment, immunosuppression, previously diagnosed hearing loss or anatomical abnormalities predisposing to AOM, and otoscopy experience of the parent.

Intervention group:

Parents receive a digital otoscope (The Ear Puffin by Sibbo Medical Devices, MDR EU Class I device) and training on TM image interpretation. They complete a TM image classification quiz before and after the training. During follow-up, parents perform home otoscopy when suspecting AOM, capture TM images/videos, interpret findings, and record symptoms in a diary. If AOM is suspected or the child appears ill, medical evaluation is instructed.

Control group:

Standard care without home otoscopy. Parents complete the same symptom diary and seek care according to usual practice.

Statistical analyses will compare outcomes between groups. AI-based TM classification will be compared against expert panel evaluation.

This is a pilot study with a target sample size of 20 children per arm, limited by device availability.

Ethical aspects, data collection and handling The study will be conducted in accordance with the Declaration of Helsinki. Written informed consent will be obtained from all parents after provision of oral and written information. Participation is voluntary, and families may withdraw at any time. Investigators may discontinue participation if deemed in the child's best interest.

The digital otoscope is a CE-marked Class I medical device used solely for visual inspection of the tympanic membrane. Pneumatic pumps are not provided. Potential risks include minor ear canal abrasions or discomfort; serious adverse events are considered rare. Any adverse events will be managed according to standard clinical practice and reported to relevant authorities when required. The study is investigator-initiated. The device manufacturer provides the otoscopes but has no role in study design, data access, or analysis.

Data will be collected via paper symptom diaries, monthly REDCap questionnaires (University of Turku), and national electronic health records (Kanta). TM images and videos will be securely stored and imported into a research database with relevant metadata.

All data will be handled in accordance with the EU General Data Protection Regulation (GDPR 2016/679). Study data will be pseudonymized and identified only by study ID numbers. The key linking personal identifiers to study IDs will be stored separately and securely. Paper diaries will be destroyed after digitalization. Consent includes permission to access health records and to use collected images and data for scientific purposes. Results will be published in peer-reviewed journals and as part of a doctoral thesis.

Being tested
Assigning of a digital otoscope to the families in the intervention group
Keywords
acute otitis media, otitis media, digital otoscopy, telemedicine
Medical subject headings
Otitis Media

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Assigning of a digital otoscope to the families in the intervention groupDevice

    Parents receive a digital otoscope (The Ear Puffin by Sibbo Medical Devices, MDR EU Class I device) and training on TM image interpretation. They complete a TM image classification quiz before and after the training. During follow-up, parents perform home otoscopy when suspecting AOM, capture TM images/videos, interpret findings, and record symptoms in a diary. If AOM is suspected or the child appears ill, medical evaluation is instructed.

Study groups in NCT07640568
Study groupRoleWhat they receive
Intervention groupExperimentalIntervention group to receive the digital otoscope
Receives: Device: Assigning of a digital otoscope to the families in the intervention group
Control groupNo interventionControl group with no intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of physician visits due to suspected AOM

    Number of physician visits due to suspected AOM

    Measured: 5 to 9 months, depending on date of recruitment

Secondary outcomes (7)
  1. Agreement between parent interpretation, AI classifier, and expert gold standard

    Parent's interpretation of the tympanic membrane image is retrospectively compared to the expert's gold standard and classification by an artificial intelligence classifier

    Measured: 5 to 9 months, depending on date of recruitment

  2. Antibiotic prescription rates

    Antibiotic prescription rates for AOM in both arms

    Measured: 5 to 9 months, depending on date of recruitment

  3. Adverse events related to otoscopy

    Adverse events, such as abrasion, related to otoscopy in the experimental group

    Measured: 5 to 9 months, depending on date of recruitment

  4. AOM-related complications

    AOM-related complications, such as mastoiditis, in both arms

    Measured: 5 to 9 months, depending on date of recruitment

  5. Daycare absence

    Child's absence from daycare due to suspected AOM

    Measured: 5 to 9 months, depending on date of recruitment

  6. Parental work absenteeism

    Parental work absenteeism due to suspected AOM

    Measured: 5 to 9 months, depending on date of recruitment

  7. Parental satisfaction on a visual analog scale (VAS)

    Parental satisfaction in the experimental group of AOM management with parent-led digital otoscopy

    Measured: 5 to 9 months, depending on date of recruitment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jun 2026
  2. Study start1 Sep 2026
  3. Primary completion31 May 2027 (estimated)
  4. Study completion31 Aug 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07640568
Sponsor's protocol ID
VARHA/4418/13.02.01/2026
Acronym
PARENT-EAR
Status last verified
Sep 2026
First submitted
27 May 2026
Last updated
8 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Deidentified participant data will be made available upon reasonable request from the corresponding author.

Publications

  • Nuuttila S, Vallin A, Klockars T, Ruohola A, Laine M, Ivaska LE, Tahtinen PA. An artificial intelligence classifier as a screening tool to rule out otitis media in children. Int J Pediatr Otorhinolaryngol. 2026 Jun;205:112847. doi: 10.1016/j.ijporl.2026.112847. Epub 2026 May 9.

    PubMed 42114455

Questions about this trial

What is this clinical trial studying?

A study testing Assigning of a digital otoscope to the families in the intervention group in people with Acute Otitis Media and Otitis Media, run by Turku University Hospital at 2 sites in Finland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 8 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Simo Nuuttila, MD (+358503314426, simo.c.nuuttila@utu.fi), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of physician visits due to suspected AOM (time frame: 5 to 9 months, depending on date of recruitment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07640568, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in